Print Page     Close Window     

SEC Filings

6-K
IKANG HEALTHCARE GROUP, INC. filed this Form 6-K on 12/21/2018
Entire Document
 

 

Income from Operations

 

Income from operations for the period was US$42.2 million, representing a 2.0% increase from US$41.3 million for the same period of the last fiscal year. Excluding share-based compensation expenses of US$526,000 for this period and US$773,000 for the same period of the last fiscal year, non-GAAP income from operations for the period was US$42.7 million as compared to US$42.1 million for the same period of last fiscal year, which reflected a rise of 1.4%.

 

Non-GAAP EBITDA

 

Non-GAAP EBITDA for the period was US$64.4 million, representing a 2.7% increase from US$62.7 million for the same period of the last fiscal year.  Non-GAAP EBITDA margin for the period was 19.6% as compared to 23.4% for the same period of the last fiscal year.

 

Net Income

 

Net income attributable to the Company for the period was US$22.4 million, representing a 2.9% decrease from US$23.1 million for the same period of the last fiscal year.

 

Non-GAAP net income for the period was US$22.9 million, representing a 3.9% decrease from US$23.8 million for the same period of fiscal 2017.  Non-GAAP net income margin for the period was 7.0% as compared to 8.9% for the same period of the last fiscal year.

 

Basic and Diluted Income per ADS

 

Basic and diluted income per ADS attributable to common shareholders were US$0.32 and US$0.31, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.34 and US$0.33, respectively, in the first fiscal six months 2017.

 

Non-GAAP basic and diluted income per ADS attributable to common shareholders were US$0.33 and US$0.32, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.35 and US$0.34, respectively, in the first fiscal six months 2017.

 

Cash and Cash Equivalents

 

As of September 30, 2018, the Company’s cash and cash equivalents and restricted cash totaled US$38.3 million, as compared to US$46.4 million as of June 30, 2018.

 

5



Copyright © 2015- iKang Healthcare Group, Inc. All Rights Reserved.